Browse > Article

Valproate-associated weight gain and potential predictors in children with epilepsy  

Jang, Gook Chan (Department of Pediatrics, College of Medicine, Chosun University)
Kim, Eun Young (Department of Pediatrics, College of Medicine, Chosun University)
Rho, Young Il (Department of Pediatrics, College of Medicine, Chosun University)
Moon, Kyung Rye (Department of Pediatrics, College of Medicine, Chosun University)
Park, Sang Kee (Department of Pediatrics, College of Medicine, Chosun University)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.5, 2007 , pp. 484-488 More about this Journal
Abstract
Purpose : The purpose of this study was to determine the incidence and potential predictors of weight gain in older children and teens treated with valproate (VPA) for epilepsy. Methods : Sixty-five subjects aged 8 to 17 years of age, who began VPA treatment between January 1, 2001, and December 31, 2004, and who had documented weight and height measurements at medication initiation and at least one follow-up visit were retrospectively identified. Exclusion criteria were follow-up <6 months, discontinuation of VPA within 6 months, and concurrent therapy with medication known to affect weight (such as topiramate, carbamazepin). Body mass index (BMI) was calculated at initiation and either discontinuation of VPA or last follow-up and stratified into four categories: group 1, underweight <5%; group 2, appropriate 5-85%; group 3, potentially overweight 85-95%; group 4, overweight >95%. Results : Twenty-eight subjects (77.8%) remained within their same category and eight (22.2%) moved up at least one category. Weight gain (increase in BMI difference) was observed in 72.2% of the 36 subjects treated with VPA. Three factors, neurocognitive status (P=0.017), seizure type (P=0.001) and duration of VPA treatment (P=0.035) were identified to be significant predictors of BMI difference. Conclusion : VPA induces weight gain in children and teens with epilepsy. These factors which are normal neurocognitive status, primary generalized type and duration of VPA treatment over the 12 months were predictors for an increase of weight gain. Therefore potential weight gain should be discussed with patients before the initiation of therapy and BMI should be monitored closely.
Keywords
Valproic acid; Weight gain; Body mass index;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Maffei M, Halaas J, Ravussin E. Leptin level is human and Rodent: measurement of plasma leptin and ob gene RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155- 61   DOI
2 Dornhorst A, Jenkins JS. The evaluation of sodium valproate treatment of Nelson's syndrome. J Clin Endocrinol Metab 1983;56:985-91   DOI
3 Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-4   DOI
4 Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7   DOI   ScienceOn
5 Demir E, Aysun S. Weight gain associated with valproate in children. Pediatr Neurol 2000;22:361-4   DOI   ScienceOn
6 Wirrell EC, Camfield CS, Camfield PR, Dooley JM, Gordon KE, Smith B. Long-term psychosocial outcome in typical absence epilepsy: Sometimes a wolf in sheeps' clothing. Arch Pediatr Adolesc Med 1997;151:152-8   DOI   ScienceOn
7 Austin JK, Smith MS, Risinger MW, McNelis AM. Childhood epilepsy and asthma: Comparison of quality of life. Epilepsia 1994;35:608-15   DOI   ScienceOn
8 Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28: 126-9   DOI   ScienceOn
9 Verrotti A, Basciani F, Moresi S, de Martino M, Morgese G, Hiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2   DOI
10 Isojarvi JI, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS. Valproate, lamotrigen, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-51   DOI   ScienceOn
11 Kim IC, Kim ES, Bae EJ, Park WI, Lee HG, Lee KJ. The pattern of weight gain and change of peripheral serum lipid profiles in idiopathic epileptic children treated with valproate. J Korean Child Neurol Soc 2002;10:81-6
12 Yoon WS, Ryu NE, Woo YJ. Serum leptin levels in epileptic children with anticonvulsant medication. J Korean Child Neurol Soc 1999;6:285-9
13 Turnbull DM, Dick DJ, Wilson L, Sherratt HS, Alberti KG. Valproate causes metabolic disturbance in normal man. J Neurol Neurosurg Psychiatry 1986;49:405-10   DOI
14 Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981; 283:577-81   DOI
15 Breum L, Astrup A, Gram L. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992;41:S29-37
16 Astrup AV. Sodium valproate promotes obesity by reducing energy expenditure. Int J Obesity 1983;13:126
17 Panksepp J, Meeker RB. The role of GABA in the ventro medical hypothalamic regulation of food intake. Brain Res Bull 1980;5:453-60   DOI   ScienceOn
18 Kim SJ, Park HS, Hwang JS, Jung YJ, Ko TS. Change of body weight according to antiepileptic drugs in children with epilepsy: Valproic Acid vs. Topiramate. J Korean Child Neurol Soc 2003;11;68-72
19 Rogers V, Vandenberghe Y, Vercruysse A. Inhibition of gluconeogenesis by so dium valproate and its metabolites in rat hepatocytes. Xenobiotica 1985;15:759-65   DOI   ScienceOn
20 Shoenfeld WN, Warden CH. Pediatric obesity. An overview of etiology and treatment. Pediatric Clin North Am 1997;44; 339-61   DOI
21 Isojarvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39:579-84   DOI   ScienceOn
22 Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: Relation to obesity. Epilepsy Res 1993;16:55-64   DOI   ScienceOn
23 Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70:65-9
24 Considine RV, Sinha MK, Heiman ML. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;34:292-5